Results 231 to 240 of about 299,603 (337)

Preventing Overrides of Severe Drug Allergy Alerts Initiative: an Implemented System Upgrade. [PDF]

J Med Syst
Abu Esba LC, Al Moaiseib S, BinSabbar NS, Al Mardawi GHS, Alkatheri M, Al Dekhail S.   +5 more
europepmc   +1 more source

Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug.
Amanda L. Stapleton, Adam Kimple, Jennifer L. Goralski, Daniel M. Beswick, Anshika Gupta, Douglas A. Li, Barton F. Branstetter, S. Mehdi Nouraie, Amber D. Shaffer, Brent Senior, Anna C. Zemke   +10 more
wiley   +1 more source

How to Define and Manage Low-Risk Drug Allergy Labels. [PDF]

J Allergy Clin Immunol Pract
Copaescu AM, Li L, Blumenthal KG, Trubiano JA.   +3 more
europepmc   +1 more source

Shared Interoperable Clinical Decision Support Service for Drug-Allergy Interaction Checks: Implementation Study.

JMIR Med Inform, 2022
Jung S, Bae S, Seong D, Oh OH, Kim Y, Yi BK.   +5 more
europepmc   +1 more source

Drug Allergy in children: focus on beta-lactams and NSAIDs. [PDF]

Acta Biomed, 2020
Cravidi C, Caimmi S, De Filippo M, Martelli A, Caffarelli C, Miraglia Del Giudice M, Calvani M, Tosca MA, Cardinale F, Marseglia GL, Manti S, Chiappini E, Caimmi D.   +12 more
europepmc   +1 more source

Anaphylaxis during general anaesthesia: experience from a drug allergy centre in the UK [PDF]

, 2017
Juan Meng, Guiseppina Rotiroti, Edward Burdett, Joanna Lukawska   +3 more
openalex   +1 more source

Thrombocytopenia and Anemia After Cardiac Surgery

American Journal of Hematology, EarlyView.
Myriam Beshai, Nour Alhomsi, Theodore E. Warkentin   +2 more
wiley   +1 more source

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation.
Margaux Petitjean, Alexia Letierce, Anne‐Sophie Bonnel, Philippe Reix, Eric Deneuville, Nathalie Stremler, Romain Luscan, Vincent Couloigner, Laurent Mely, Katia Bessaci, Guillaume Labbe, Christophe Marguet, Mairead Kelly‐Aubert, Fatiha Hassani, Isabelle Sermet‐Gaudelus, François Simon, the MODUL‐CF Study Group   +16 more
wiley   +1 more source

Impact of a drug allergy education course for non-specialists: Findings from ADAPT-A randomized crossover trial. [PDF]

Allergy
Lucas M, Mak HWF, Lee JTY, Kulkarni R, Chan SSC, Li PH.   +5 more
europepmc   +1 more source

Psychological profiles of patients with suspected drug allergy. [PDF]

Asia Pac Allergy, 2020
Dias de Castro E, Leblanc A, Barbosa J, Ribeiro L, Cernadas JR.   +4 more
europepmc   +1 more source